NEW YORK (GenomeWeb News) – Roche today announced agreements to develop a diagnostic assay for the detection of epidermal growth-factor receptor mutations and a PCR-based companion diagnostic test to identify patients with non-small cell lung cancer with EGFR-activating mutations.
In separate agreements, Roche has obtained a worldwide sub-license from Genzyme to develop the EGFR assay, and will collaborate with OSI Pharmaceuticals to develop the companion diagnostic.